Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jiadai,Zhai

第一单位： School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China.

作者： Jiadai,Zhai ^[1] ; Chuang,Li ^[2] ; Bingxia,Sun ^[2] ; Sinan,Wang ^[2] ; Yuting,Cui ^[2] ; Qingzhi,Gao ^[3] ; Feng,Sang ^[4]

作者单位： School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China. ^[1] School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255049, PR China. ^[2] School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, PR China. Electronic address: qingzhi@tju.edu.cn. ^[3] School of Life Sciences and Medicine, Shandong University of Technology, Zibo 255049, PR China. Electronic address: fengsang@sdut.edu.cn. ^[4]

关键词 Anticancer Proteolysis targeting chimeras Sunitinib Synthesis von Hippel-Lindau

主题词人类(Humans);白血病(Leukemia);HL-60细胞(HL-60 Cells);蛋白酶体内肽酶复合物(Proteasome Endopeptidase Complex)

DOI 10.1016/j.bmcl.2022.129041

PMID 36332882

发布时间 2022-11-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交